FIELD: medicine; pharmaceutics.
SUBSTANCE: disclosed is a suspension formulation for treating a disease or disorder, comprising a spray-dried monoclonal antibody in concentration of 200 to 500 mg/ml suspended in a non-aqueous suspension vehicle, where viscosity of filler for suspension is less than 20 cP at 25 °C and where the non-aqueous filler for the suspension contains ethyl lactate. Group of inventions also relates to a device for subcutaneous administration containing said composition, a method of producing said device and an embodiment of said suspension formulation, wherein the antibody is a full-length human IgG1 monoclonal antibody.
EFFECT: invention provides a highly concentrated composition with low viscosity.
24 cl, 10 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
| ANTIBODIES BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2015 |
|
RU2730674C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| ANTI-SIGLEC-9 ANTIBODY MOLECULES | 2020 |
|
RU2833330C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| EphA4 ANTIBODY | 2016 |
|
RU2719158C2 |
| NON-VIRAL IMMUNOTARGETING | 2020 |
|
RU2833379C2 |
